OUR PIPELINE
MS
ONCOLOGY
| REGIMEN | DIsease | Preclinical | Phase 1 | Phase 2 | Phase 3 | Registration Status | Learn More | |
|---|---|---|---|---|---|---|---|---|
|
Single |
Ublituximab monotherapy: anti-CD20 mAb | Relapsing MS |
ULTIMATE I and II
|
PDUFA 12/28/2022 |  |
|||
|
Early Pipeline |
Cosibelimab (TG-1501): anti-PD-L1 mAb | B-cell malignancies | |
|||||
| TG-1701: BTK inhibitor | B-cell malignancies | |
||||||
| TG-1801: anti-CD47/CD19 bispecific mAb | B-cell malignancies | |
||||||
| TG-1601: BET inhibitor | B-cell malignancies | |
||||||
ENROLLMENT COMPLETED
ENROLLMENT ONGOING
|
Single Agent |
|||||
|---|---|---|---|---|---|
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|
MS |
Ublituximab monotherapy: anti-CD20 mAb
DiseaseRelapsing MS Learn More |
ULTIMATE I and II
PDUFA 12/28/2022 |
|||
|
EARLY PIPELINE |
||||||
|---|---|---|---|---|---|---|
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | ||
|
ONCOLOGY
|
Cosibelimab (TG-1501): anti-PD-L1 mAb
DiseaseB-cell malignancies Learn More |
|||||
|
TG-1701: BTK inhibitor
DiseaseB-cell malignancies Learn More |
||||||
|
TG-1801: anti-CD47/CD19 bispecific mAb
DiseaseB-cell malignancies Learn More |
||||||
|
TG-1601: BET inhibitor
DiseaseB-cell malignancies Learn More |
||||||
|
ENROLLMENT COMPLETED
ENROLLMENT ONGOING
|
||||||
|
The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities. |
||||||